Osteoarthritis is a chronic progressive disease where there is degeneration & loss of articular cartilage that occurs together with new bone formation at the joint surfaces and margins, that causes pain and deformity.
The patient experiences pain, stiffness, decreased movement, inflammation and crepitus.
The pain is usually aggravated by pain and relieved by rest.
Radiofrequency ablation and neuromodulation modalities for knee osteoarthritis (OA) potentially improve pain, functionality and disease-specific quality of life for up to 3–12 months with minimal localized complications, according to the results of a systematic review.
Partial knee replacement surgery provides similar clinical outcomes as total knee replacement in patients with late-stage osteoarthritis (OA), although the former proves more cost-effective according to the results of the TOPKAT* trial.
Interleukin-1 inhibition with lutikizumab does not yield substantial analgesic or anti-inflammatory effects in the treatment of patients with knee osteoarthritis (OA) and associated synovitis, with the results of a phase II trial showing limited improvement in pain and synovitis.
The antinerve growth factor fasinumab delivers significant analgesic effects in patients experiencing moderate-to-severe pain from osteoarthritis, including those benefitting little from a previous analgesic, according to the results of a phase IIB/III trial.
Greater parity, early age at menarche, or oral contraceptive use may increase a woman’s risk of undergoing total knee replacement (TKR) for severe knee osteoarthritis (OA), according to findings from the Singapore Chinese Health Study (SCHS).
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.